Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel J Taylor

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Biorxiv : the Preprint Server for Biology|March 18, 2026
Transitory enhancement of GATA2 chromatin engagement during early erythroid differentiationJohn W Hobbs, Samuel J Taylor, Rajni Kumari, et al.
Plos One|April 11, 2014
Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant miceJohanna M Duyvestyn, Samuel J Taylor, Samantha A Dagger, et al.
Blood Cancer Discovery|May 18, 2026
Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid LeukemiaGoichi Tatsumi, Rajni Kumari, Yutaro Suzuki, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2019
Runx1 promotes murine erythroid progenitor proliferation and inhibits differentiation by preventing Pu.1 downregulationMichael A Willcockson, Samuel J Taylor, Srikanta Ghosh, et al.
Experimental Hematology|February 3, 2015
The targeting of human and mouse B lymphocytes by dasatinibMorten P Oksvold, Johanna M Duyvestyn, Samantha A Dagger, et al.
Experimental Hematology|December 24, 2014
Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant miceSamuel J Taylor, Christine B F Thien, Samantha A Dagger, et al.
Science Translational Medicine|August 11, 2017
Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinibSamuel J Taylor, Johanna M Duyvestyn, Samantha A Dagger, et al.
Rheumatology (Oxford, England)|November 17, 2021
Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?Venkat R Reddy, Ruth J Pepper, Kavina Shah, et al.
Cell Reports|June 23, 2023
DNA selection by the master transcription factor PU.1J Ross Terrell, Samuel J Taylor, Amelia L Schneider, et al.
The Journal of Experimental Medicine|May 19, 2018
IL1RAP potentiates multiple oncogenic signaling pathways in AMLKelly Mitchell, Laura Barreyro, Tihomira I Todorova, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Biorxiv : the Preprint Server for Biology|March 18, 2026
Transitory enhancement of GATA2 chromatin engagement during early erythroid differentiationJohn W Hobbs, Samuel J Taylor, Rajni Kumari, et al.
Plos One|April 11, 2014
Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant miceJohanna M Duyvestyn, Samuel J Taylor, Samantha A Dagger, et al.
Blood Cancer Discovery|May 18, 2026
Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid LeukemiaGoichi Tatsumi, Rajni Kumari, Yutaro Suzuki, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2019
Runx1 promotes murine erythroid progenitor proliferation and inhibits differentiation by preventing Pu.1 downregulationMichael A Willcockson, Samuel J Taylor, Srikanta Ghosh, et al.
Experimental Hematology|February 3, 2015
The targeting of human and mouse B lymphocytes by dasatinibMorten P Oksvold, Johanna M Duyvestyn, Samantha A Dagger, et al.
Experimental Hematology|December 24, 2014
Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant miceSamuel J Taylor, Christine B F Thien, Samantha A Dagger, et al.
Science Translational Medicine|August 11, 2017
Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinibSamuel J Taylor, Johanna M Duyvestyn, Samantha A Dagger, et al.
Rheumatology (Oxford, England)|November 17, 2021
Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?Venkat R Reddy, Ruth J Pepper, Kavina Shah, et al.
Cell Reports|June 23, 2023
DNA selection by the master transcription factor PU.1J Ross Terrell, Samuel J Taylor, Amelia L Schneider, et al.
The Journal of Experimental Medicine|May 19, 2018
IL1RAP potentiates multiple oncogenic signaling pathways in AMLKelly Mitchell, Laura Barreyro, Tihomira I Todorova, et al.
Pageof 3